Objective: To investigate the association of a polymorphism at position 294 ( þ 294T/C) in the Peroxisome Proliferator-activated Receptor d (PPARd) with body mass index (BMI) and the additional role of a gene-to-gene interaction between PPARd, PPARa and PPARg. Design: An association between genetic variations in PPARd, PPARa and PPARg and indices of obesity and metabolism. Subjects: A group of 462 moderately obese (mean BMI 28.977.7) and dyslipidemic, middle-aged (mean age 43.9713.7), Caucasion men and women. Measurements: The three most frequent single-nucleotide-polymorphisms (snp) in PPARd ( þ 294T/C), PPARa (L162V) and PPARg (P12A) were genotyped and associated with clinical parameters. Results: The C allele in PPARd was significantly associated with a lower body mass index. Moreover an interaction between the polymorphisms in PPARa and PPARd on body weight could be demonstrated. Conclusion: Our data provide further evidence for an involvement of PPARd in the regulation of BMI.
Introduction
Obesity is a complex metabolic disorder that affects a growing number of patients worldwide. 1 Genetic factors play a dominant role in the determination of body mass index (BMI) in a given environmental setting. Although in the minority of cases, a single mutation leads to an obese phenotype, evidence suggests that in most obese patients, a large number of genes are involved. 2 These modifier genes may interact with one another or with environmental factors eventually leading to an increase in body weight. Single nucleotide polymorphisms (snps) in the peroxisome proliferator-activated receptor (PPAR) genes have been associated with variance in body weight. Peroxisome proliferator-activated receptors belong to a superfamily of nuclear receptors of which three different isoforms (a, d and g) have been identified. Although PPARa is mainly expressed in the liver, muscle, kidney and heart, PPARd is expressed in many tissues and PPARg is most abundant in adipocytes, intestinal cells and macrophages. [3] [4] [5] Each subgroup is activated by a certain variety of fatty acids and their derivatives and by specific pharmacological ligands. After forming obligate heterodimers with the retinoid X receptor, PPARs bind to specific elements in the promoter region of target genes called PPAR response elements, thereby altering metabolism by activating a network of downstream genes. Whereas PPARa promotes b-oxidation, PPARg has been attributed the role of a master regulator of adipocyte differentiation. Peroxisome proliferator-activated receptor PPARd has been found to be associated with low-density cholesterol (LDL) and triglyceride levels and increase the expression of genes involved in fatty acid oxidation and energy uncoupling. A number of polymophisms have been described in all three PPAR isoforms. In PPARa, the L162V (rs 1800206) polymorphism has been associated with LDL, high-density lipoprotein cholesterol (HDL) levels, increased triglycerides and abdominal obesity. 6 Recently Fu et al. 7 demonstrated that oleylethanolamide (OEA), a naturally occurring lipid structurally related to the endocannabinoid anandamide, regulates satiety and BMI through activation of PPARa in the enteric wall. The þ T294C (rs 2016520) variant in PPARd has been intensively studied in men by Skogsberg et al. 8, 9 Although in a group of 543 healthy, middle-aged male, carriers of the rare C allele had elevated levels of LDL and apolipoprotein B (Apo B), a lower HDL concentration and a higher risk for coronary heart disease was found in a different male population. Conversely, treatment of obese rhesus monkeys with the synthetic PPARd agonist GW501516 resulted in an increase of plasma HDL levels and a decrease of triglycerides. 10 In addition, db/db mice expressing an activated form of PPARd are resistant to obesity and hyperlipidemia when overfed, and muscle-specific overexpression of the receptor increased the number of muscle fiber with high oxidative metabolic capability. 11, 12 Recently,
Vänttinen et al. 13 demonstrated an increased muscle glucose uptake in C allele carriers. The P12A (rs 1801282) variation in PPAR g is probably the most intensively investigated snp of PPARs. However, in cross-sectional studies, no consistent results were obtained concerning its influence on BMI. Although in a Finish cohort, a lower BMI was found in carriers of the rare allele, other authors found no or only a moderate increase in BMI or markers of the metabolic syndrome. 14, 15 An interaction between genotypes of PPARd and PPARa has been demonstrated previously in a group of healthy and normal weight men. 8 However, it is currently unclear whether corresponding gene-to-gene interactions are also relevant in the situation of overweight and/or hyperlipidemia. Therefore, we chose a group of 462 obese dyslipidemic men and women to study gene-to-gene interactions related to measures of the metabolic syndrome.
Materials and methods

Patients
All subjects were recruited between 2000 and 2004 from patients who attended the medical/obesity outpatient clinic of the University of Hamburg Hospital. Table 1 summarises the patient characteristics. All patients were of Caucasian origin and to our knowledge no related subjects were among the samples. Informed consent was obtained from every patient and the study was approved by the local ethics commission. All patients received dietary advise in a 30-60-min discussion with a dietary assistant, in which they were instructed to reduce their daily fat intake to a maximum of 40-60 g depending on their BMI. Patient compliance was supervised by handing out a nutritional diary, which was submitted at each of the further visits to the clinic. After 6 weeks, the patients again attended the clinic and lipid values as well as biometric data were obtained once again.
Biochemical measurements
Plasma total cholesterol and triglycerides were determined using GPO-PAP and CHOD-PAP kits, respectively, from Boehringer Mannheim (Mannheim, Germany). High-density lipoprotein was measured following precipitation of apoBcontaining lipoproteins with phosphotungstate (Boehringer Mannheim). Apoliprotein AI and Apo B were measured using the Beckman Array 360 (Beckman Instruments, GmbH, München, Germany).
Genotyping DNA was extracted from white blood cells using standard methods. For the þ 294T/C polymorhism, a mutagenically separated polymerase chain reaction (MS-PCR) was developed to separate wildtype (wt) and mutated alleles as described. 16 The longer primer for detection of the wt allele was 5 0 -TTC AAG CCC TGA TGA TAA GGT CTT TGG CAT  TAG ATG CTG TTT TGT TTT-3 0 . The shorter primer was 5 0 -CTT TTG GCA TTA GAT GCT GTT TTG TCC TG-3 0 . As reverse primer, we used 5 0 -CTT CCT CCT GTG GCT GCT C-3 0 . PCR conditions were: 961C for an intial 5 min followed by 961C 1 min, 651C 1 min, 721C 1 min for 43 cycles and final extension at 721 for 10 min. Mutagenically separated PCR created two fragments of divergent length, which were detected by silver staining on polyacrylamide gel. For the L162V polymorphism in PPARa, and the P12A mutation in PPARg, determination of the genotype was performed as described previously. 17, 18 Statistical analysis Allele frequencies were determined by gene counting and compared using the w 2 test. The data were analyzed using SPSS 12.0 software. The association between the þ 294T/C 
Results
The frequency of the mutant alleles were found to be 0.25 ( þ 294T/C), 0.12 ((P12A) and 0.11 (L162V) and all genotypes were distributed according to Hardy-Weinberg equilibrium. Overall, patients were moderately obese and presented with mixed hyperlipidemia. Patient characteristics are presented in Table 1 . None of the participating individuals had a total cholesterol 4500 mg/dl or triglycerides greater than 1000 mg/dl. Average weight loss under fat restriction was B1 kg within 6 weeks. Biometric data and lipid parameters according to genotype are presented in Table 2 . C allele carriers had a significantly lower absolute body weight and BMI than TT homozygotes (Figure 1 ). Weight loss under diet was not different between both groups. There was a trend towards higher total cholesterol, LDL and apolipoprotein B in individuals carrying the CT or CC genotype; however, the differences were not statistically significant. Carriers of the rare A allele in PPARg had a significantly lower HDL, whereas only a tendency was seen for total cholesterol and LDL. PPARa V allele carriers had a slightly higher mean total cholesterol and LDL and a lower mean body weight and BMI. However, these differences were not statistically significant.
A potential gene-to-gene interaction between the polymorphisms was studied. No interactive effect was observed between the PPARa and PPARg variants (data not shown). In contrast, interaction between the PPARa and PPARd genotypes had significant effects on baseline BMI and body weight (Figure 2) .
A trend was noted toward an interactive effect on BMI between the PPARd and PPARg genotypes (Figure 3) . In contrast, no interaction was observed with respect to the lipid variables. 
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Discussion and conclusions
In this communication, we show that the þ 294C allele in PPARd is associated significantly with lower body weight and BMI in a group of 517 moderately obese and mixed dyslipidemic patients. Current evidence suggests an important role of PPARd in energy storage and dissipation. In an animal study, Wang et al. 19 could show that activation of PPARd through a selective agonist reduced fatty acid storage in adipocytes and prevented development of obesity under high-fat diet. This is in agreement with results obtained by Oliver et al., 10 who showed that treatment of obese rhesus monkeys with GW 501516, a selective PPARd agonist, led to a significant improvement of metabolic traits characterized by a rise of HDL and lowering of LDL, triglycerides and insulin.
Considering that a higher basal transcriptional activity has been linked to the C allele, our results obtained in human patients are in line with these animal studies. In contrast, Skogsberg et al. 8 found a deterioration of metabolic traits in carriers of the C allele in two independent groups of either healthy or dyslipidemic men. 8, 9 Of note, the BMI of both study cohorts was significantly lower than in our group. We currently presume that the multiple shift in gene activation and repression occurring in obesity may modulate the effect of the polymorphism, thereby leading to divergent results. The P12A polymorphism in PPARg is clearly associated with a reduced risk for the development of type 2 diabetes mellitus. Considering the key role of PPARg in the differentiation of adipocytes and the moderate reduction of transcriptional activity associated with the A allele, one would expect a reduction of BMI in the mutant genotype. However, the results are inconsistent, presumably because the improvement of insulin sensitivity is transmitted primarily through the expression of adipocytokines. 20 A rise in HDL, as seen in our group, may reflect a reduction in insulin resistance in A allele carriers without changes of body weight. The L162V polymorphism in PPARa has been investigated intensively. Most authors found an association between the V allele and traits of the metabolic syndrome, including abdominal obesity. A gene-to-diet interaction was noted by Robitaille et al. 21 The intake of fat explained a significant percentage of the variation seen between the genotypes. Additionally in the work of Fu et al., 7 the induction of enteric PPARa expression by OEA led to a decrease of food intake in mice. 7 Therefore, the effect of PPARa on obesity and lipid metabolism may depend on the amount of ingested fat. In our group, no significant associations between the C allele and metabolic parameters could be detected. However, the amount of daily fat ingestion was not included in the evaluation. An interaction between PPARa and PPARd genotypes has been previously investigated by Skogsberg et al. 8 In their study, an interactive effect between the polymorphisms on plasma LDL and triglycerides was noted. In our study, we could detect a significant effect of a gene-to-gene interplay of both receptors on body weight and BMI (P ¼ 0.02). Adding the C allele to the analysis resulted in a significant increase of BMI (Figure 2 ). For the P12A variant, a similar trend was observed, but this did not reach significant differences (Figure 3) . Activation of PPARd prevents the development of obesity in various animal species. Considering that the C-allele is Role of PPARd in obesity J Aberle et al associated with a higher transcriptional activity, it is conceivable that C allele carriers exhibit a lower body weight. If, however, the activation of PPARa through OEA or other ligands in the intestine is impaired, as would be expected in PPARa V allele carriers, the protective effects of the C allele may be overcome owing to insufficient production of satiety signals resulting in an increase of body weight.
In conclusion, our results support an important role of PPARd in body weight regulation and confirm the hypothesis of a polygenetic origin of obesity.
